Affiliations 

  • 1 School of Pharmacy, University of Nottingham Malaysia, Semenyih, Malaysia
  • 2 Center for Cancer and Stem Cell Research, International Medical University, Kuala Lumpur, Malaysia
Pharm Dev Technol, 2021 Feb;26(2):243-251.
PMID: 33274672 DOI: 10.1080/10837450.2020.1860087

Abstract

Tocotrienol (TRF) ethosomes were developed and evaluated in vitro for potential transdermal delivery against melanoma. The optimised TRF ethosomal size ranged between 64.9 ± 2.2 nm to 79.6 ± 3.9 nm and zeta potential (ZP) between -53.3 mV to -62.0 ± 2.6 mV. Characterisation of the ethosomes by ATR-FTIR indicated the successful formation of TRF-ethosomes. Scanning electron microscopy (SEM) images demonstrated the spherical shape of ethosomes, and the entrapment efficiencies of all the formulations were above 66%. In vitro permeation studies using full-thickness human skin showed that the permeation of gamma-T3 from the TRF ethosomal formulations was significantly higher (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.